Guess Who Picked Nexvet Biopharma Plc. (NASDAQ:NVET) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nexvet Biopharma Plc. (NASDAQ:NVET) reported that Farallon Capital has picked up 1,046,345 of common stock as of 2017-04-19.
The acquisition brings the aggregate amount owned by Farallon Capital to a total of 1,046,345 representing a 8.7% stake in the company.
For those not familiar with the company, Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
A glance at Nexvet Biopharma Plc. (NASDAQ:NVET)’s key stats reveals a current market capitalization of 77.57 Million based on 11.75 Million shares outstanding and a price at last close of $6.61 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Gearing picked up 9,000 at a purchase price of $3.35. This brings their total holding to 125,903 as of the date of the filing.
On the sell side, the most recent transaction saw Farrell unload 132 shares at a sale price of $3.27. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nexvet Biopharma Plc. (NASDAQ:NVET) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) reported that Baker Bros. Advisors has picked up 10,934,154 of common stock as of 2017-03-27.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 10,934,154 representing a 46.7% stake in the company
For those not familiar with the company, Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.
A glance at Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s key stats reveals a current market capitalization of 375.12 Million based on 23.42 Million shares outstanding and a price at last close of $15.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-09, Baker picked up 32,051 at a purchase price of $17.76. This brings their total holding to 9,764,459 as of the date of the filing.
On the sell side, the most recent transaction saw Mackenzie unload 35,887 shares at a sale price of $18.67. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.